1-6 of 6
Keywords: Cardiotoxicity
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Clin Sci (Lond) (2022) 136 (11): 841–860.
Published: 01 June 2022
... to cardiotoxicity following a high cumulative dose of doxorubicin (DOX). A mitochondrial division inhibitor-1 (Mdivi-1) and fusion promoter (M1) have been shown to be cardioprotective in a variety of cardiovascular settings, however, their anticardiotoxic efficacy against DOX therapy remains unclear. We therefore...
Clin Sci (Lond) (2022) 136 (1): 139–161.
Published: 07 January 2022
... on chronic ANT cardiotoxicity in a rabbit model previously validated with the cardioprotective agent dexrazoxane (DEX) with focus on post-treatment follow-up (FU). Chronic cardiotoxicity was induced by daunorubicin (DAU; 3 mg/kg/week for 10 weeks). Perindopril (0.05 mg/kg/day) was administered before...
Includes: Supplementary data
Clin Sci (Lond) (2021) 135 (10): 1311–1332.
Published: 28 May 2021
... © 2021 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society 2021 anthracycline cardiomyopathy cardiotoxicity reactive oxygen species topoisomerases Anthracyclines are highly effective chemotherapeutic agents that remain a cornerstone...
Includes: Supplementary data
Clin Sci (Lond) (2020) 134 (19): 2595–2622.
Published: 14 October 2020
... clinical implications of treating patients with these drugs, such as increased arrhythmia burden, biventricular cardiac dysfunction, and impaired recovery from cardiotoxicity. Recommendations for future directions for preclinical and clinical work are made, highlighting the possible role of PI3Kα...
Clin Sci (Lond) (2020) 134 (13): 1859–1885.
Published: 17 July 2020
...Keith Dadson; Oscar Calvillo-Argüelles; Paaladinesh Thavendiranathan; Filio Billia Despite the known risk of cardiotoxicity, anthracyclines are widely prescribed chemotherapeutic agents. They are broadly characterized as being a robust effector of cellular apoptosis in rapidly proliferating cells...
Clin Sci (Lond) (2019) 133 (16): 1827–1844.
Published: 27 August 2019
... inhibitors (PIs) are modern targeted anticancer drugs, they have been associated with a certain risk of cardiotoxicity and heart failure (HF). Recently, PIs have been combined with anthracyclines (ANTs) to further boost their anticancer efficacy. However, this raised concerns regarding cardiac safety, which...
Includes: Supplementary data